Emerging issues in mouse liver carcinogenesis

Toxicologic Pathology

Volumn 24, Issue 1, 1996, Pages 129-137

  Ward, Jerrold M ^a   Shibata, Masa Aki ^a   Devor, Deborah E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

bioassay; cell proliferation; H ras; Hepatocarcinogenesis; nongenotoxic carcinogens

Indexed keywords

CARCINOGEN; CLOFIBRATE; GRISEOFULVIN; METRONIDAZOLE; MEVINOLIN; ORCIPRENALINE; OXAZEPAM; PHENAZOPYRIDINE; PHENOBARBITAL; SERTRALINE; SIMVASTATIN; VIDARABINE;

ANIMAL MODEL; CONFERENCE PAPER; GENE MUTATION; HISTOPATHOLOGY; HORMONE ACTION; LIVER CANCER; LIVER CARCINOGENESIS; LIVER PARENCHYMA; LIVER TOXICITY; MOUSE; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL;

EID: 0030041188     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1177/019262339602400117     Document Type: Conference Paper

References (87)

1. Ames BN, Gold LS, and Willett WC (1995). The causes and prevention of cancer. Proc. Natl. Acad. Sci. USA 92: 5258-5265.
2. Anderson MW and Maronpot RR (1993). Methylene chloride-induced tumorigenesis. Carcinogenesis 14: 787-788.
3. Bucher JR, Shackelford CC, Haseman JK, Johnson JD, Kurtz PJ, and Persing RL (1994). Carcinogenicity studies of oxazepam in mice. Fundam. Appl. Toxicol. 23: 280-297.
4. Butterworth BE, Slaga TJ, Farland W, and McClain M (1991). Chemically induced cell proliferation: Implications for risk assessment. Prog. Clin. Biol. Res. 369: 1-546.
5. Chu KC, Cueto C Jr, and Ward JM (1981). Factors in the evaluation of 200 National Cancer Institute carcinogen bioassays. J. Toxicol. Environ. Health 8: 251-280.
6. Davies TS and Monro A (1995). Marketed human pharmaceuticals reported to be tumorigenic in rodents. J. Am. Coll. Toxicol. 14(2): 90-107.
7. Diwan BA, Ward JM, Kurata Y, and Rice JM (1994). Dissimilar frequency of hepatoblastomas and hepatic cystadenomas and adenocarcinomas arising in hepatocellular neoplasms of D2B6F1 mice initiated with N-nitroso-diethylamine, and subsequently given Aroclor-1254, dichlorodiphenyltrichloroethane, or phenobarbital. Toxicol. Pathol. 22(4): 430-439.
8. Diwan BA, Ward JM, and Rice JM (1991). Modification of liver tumor development in rodents. In: Modification of Tumor Development in Rodents, N Ito and H Sugano (eds). S Karger, Basel, pp. 76-107.
9. Dragani TA, Manenti G, and Della Porta G (1981). Genetic susceptibility to murine hepatocarcinogenesis is associated with high growth rate of NDEA-initiated hepatocytes. J. Cancer Res. Clin. Oncol. 113: 223-229.
10. Fernandez-Salguero P, Pineau T. Hilbert DM, McPhail T, Lee SST, Kimura S, Nebert DW, Rudikoff S, Ward JM, and Gonzalez FJ (1995). Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science 268: 722-726.
11. Foley JF, Tuck PD, Ton T-VT, Frost M, Kari F, Anderson MW, and Maronpot RR (1993). Inhalation exposure to a hepatocarcinogenic concentration of methylene chloride does not induce sustained replicative DNA synthesis in hepatocytes of female B6C3F1 mice. Carcinogenesis 14: 811-817.
12. Frith CH and Ward JM (1979). A morphologic classification of proliferative and neoplastic hepatic lesions in mice. J. Environ. Pathol. Toxicol. 3: 329-351.
13. Frith CH and Ward JM (1988). Color Atlas of Neoplastic and Non-neoplastic Lesions in Aging Mice. Elsevier, Amsterdam, pp. 1-109.
14. Frith CH, Ward JM, and Turusov VS (1994). Tumours of the liver. In: Pathology of Tumours in Laboratory Animals, V Turusov and U Mohr (eds). International Agency for Research in Cancer, Lyon, France, pp. 223-269.
15. Fu PP, Dooley KL, Von Tungeln LS, and Bucci T (1994). Caloric restriction profoundly inhibits liver tumor formation after initiation by 6-nitrochrysene in male mice. Carcinogenesis 15(2): 159-161.
16. Gold LS, Bernstein L, Magaw R, and Slone TH (1989). Interspecies extrapolation in carcinogenesis: Prediction between rats and mice. Environ. Health Perspect. 81: 211-219.
17. Gold LS, Slone TH, Manley NB, and Bernstein L (1991). Target organs in chronic bioassays of 533 chemical carcinogens. Environ. Health Perspect. 93: 233-246.
18. Gold LS, Slone TH, Stern BR, and Bernstein L (1993). Comparison of target organs of carcinogenicity for mutagenic and non-mutagenic chemicals. Mutat. Res. Fundam. Mol. Mech. Mutagen. 286: 75-100.
19. Gold LS, Ward JM, Bernstein L, and Stern B (1986). Association between carcinogenic potency and tumor pathology in rodent carcinogenesis bioassays. Fundam. Appl. Toxicol. 6: 677-690.
20. Goldfarb S and Pugh TD (1990). Ovariectomy accelerates the growth of microscopic hepatocellular neoplasms in the mouse: Possible association with whole body growth and fat deposition. Cancer Res. 50: 6779-6782.
21. Goodman JI, Ward JM, Popp JA, Klaunig JE, and Fox TR (1991). Mouse liver carcinogenesis: Mechanisms and relevance. Fund. Appl. Toxicol. 17: 651-665.
22. Harada T, Maronpot RR, Enomoto A, Tamano S, and Ward JM (1996). Age-related changes in the liver and gallbladder. In: Pathobiology of The Aging Mouse, DL Dungworth, U Mohr, JM Ward, JP Sundberg, and W Carlton (eds). ILSI Press, Washington, D.C. (in press).
23. Haseman JK, Huff JE, Rao GN, and Eustis SL (1989). Sources of variability in rodent carcinogenicity studies. Fundam. Appl. Toxicol. 12: 793-804.
24. Hoel DG, Haseman JK, Hogan MD, Huff J, and McConnell EE (1988). The impact of toxicity on carcinogenicity studies: Implications for risk assessment. Carcinogenesis 9: 2045-2052.
25. Huff JE (1995). Mechanisms, chemical carcinogenesis, and risk assessment: Cell proliferation and cancer. Am. J. Ind. Med 27: 293-300.
26. Huff J, Cirvello J, Haseman J, and Bucher J (1991). Chemicals associated with site-specific neoplasia in 1394 long-term carcinogenesis experiments in laboratory rodents. Environ. Health Perspect. 93: 247-270.
27. Huff JE, Eustis SL, and Haseman JK (1989). Occurrence and relevance of chemically induced benign neoplasms in long-term carcinogenicity studies Cancer Metastasis Rev. 8: 1-22.
28. Ito N, Hananouchi M, Sugihara S, Shirai T, Tsuda H, Fukushima S, and Nagasaki H (1976). Reversibility and irreversibility of liver tumors in mice induced by the α isomer of 1,2,3,4,5,6-hexachlorocyclohexane. Cancer Res. 36: 2227-2234.
29. Jang JJ, Weghorst CW, Henneman JR, Devor DE, and Ward JM (1992). Progressive atypia in spontaneous and N-nitrosodiethylamine induced hepatocellular adenomas of C3H/HeNCr mice. Carcinogenesis 13: 1541-1547.
30. Klaunig JE (1993). Selective induction of DNA synthesis in mouse preneoplastic and neoplastic hepatic lesions after exposure to phenobarbital. Environ Health Perspect. 101(suppl. 5): 235-240.
31. Koen H, Pugh TD, and Goldfarb S (1983a). Hepatocarcinogenesis in the mouse: Combined morphologic-stereologic studies. Am. J. Pathol. 112: 89-100.
32. Koen H, Pugh TD, Nychka D, and Goldfarb S (1983b). Presence of alpha-fetoprotein-positive cells in hepatocellular microcarcinomas induced by single injections of diethylnitrosamine in infant mice. Cancer Res. 43: 702-708.
33. Lee SS-T, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, Fernandez-Salguero PM, Westphal H, and Gonzalez FJ (1995). Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 15: 3012-3022.
34. Lipsky MM, Tanner DC, Hinton DE, and Trump BF (1984). Reversibility, persistence, and progression of safrole-induced mouse liver lesions following cessation of exposure. In: Mouse Liver Neoplasia: Current Perspectives, JA Popp (ed). Hemisphere, New York, pp. 161-177.
35. Malarkey DE, Devereux TR, Dinse GF, Mann PC, and Maronpot RR (1995). Hepatocarcinogenicity of chlordane in B6C3F1 and B6D2F1 male mice: Evidence for regression in B6C3F1 mice and carcinogenesis independent of ras protooncogene activation. Carcinogenesis (in press).
36. Maronpot RR, Fox T, Malarkey D, and Goldsworthy T (1995). Mutations in the ras proto-oncogene: Clues to etiology and molecular pathogenesis of mouse liver tumors. Toxicology 10: 125-156.
37. Maronpot RR, Haseman JK, Boorman GA, Eustis SE, Rao GN, and Huff JE (1987). Liver lesions in B6C3F1 mice: The national toxicology program, experience and position. Arch. Toxicol. (suppl.) 10: 10-26.
38. Melnick RL (1992). Does chemically induced hepatocyte proliferation predict liver carcinogenesis? FASEB J. 6: 2698-2706.
39. Merlino G (1994). Transgenic mice: Designing genes for molecular models. In: The Liver: Biology and Pathobiology, IM Arias, JL Boyer, N Fausto, WB Jakoby, DA Schachter, and DA Shafritz (eds). Raven Press, Ltd., New York, pp. 1579-1589.
40. Moore MR, Drinkwater NR, Miller EC, Miller JA, and Pitot HC (1981). Quantitative analysis of the time-dependent development of glucose-6-phosphatase-deficient foci in the livers of mice treated neonatally with diethyl-nitrosamine. Cancer Res. 41: 1585-1593.
41. Moore MA, Nakagawa K, Satoh K, Ishikawa T, and Sato K (1987). Single GST-P positive liver cells - putative initiated hepatocytes. Carcinogenesis 8: 483-486.
42. Muskhelishvili L, Hart RW, Turturro A, and James SJ (1995). Age-related changes in the intrinsic rate of apoptosis in livers of diet-restricted and ad libitum-fed B6C3F1 mice. Am. J. Pathol. 147: 20-24.
43. Newberne PM, Suphakan V, Punyarit P, and DeCamargo J (1987). Nongeno toxic mouse liver carcinogens In: Nongenotoxic Mechanisms in Carcinogenesis, BE Butterworth and TJ Slaga (eds). Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, pp. 165-176.
44. Nims RW, Lubet RA, Jones CR, Mellini DW, and Thomas PE (1993). Comparative pharmacodynamics of CYP2B induction by phenobarbital in the male and female F344/NCr rat. Biochem. Pharmacol. 45: 521-526.
45. Ohmori T, Rice JM, and Williams GM (1981). Histochemical characteristics of spontaneous and chemically induced hepatocellular neoplasms in mice and the development of neoplasms with gamma-glutamyl transpeptidase activity during phenobarbital exposure. Histochem. J. 13(1): 85-99.
46. Pietra G, Spencer K, and Shubik P (1959). Response of newly born mice to a chemical carcinogen. Nature 183: 1689.
47. Pineau T, Fernandez-Salguero P, Lee SST, McPhail T, Ward JM, and Gonzalez FJ (1995). Neonatal lethality associated with respiratory distress in mice lacking cytochrome P450 1A2. Proc. Natl. Acad. Sci. USA 92: 5134-5138.
48. Rabes HM, Bucher T, Hartmann A, Linke I, and Dunnwald M (1982). Clonal growth of carcinogen-induced enzyme-deficient preneoplastic cell populations in mouse liver. Cancer Res. 42: 3220-3227.
49. Rao KVN and Vesselinovitch SD (1973). Age- and sex-associated diethylnitrosamine dealkylation activity of the mouse liver and hepatocarcinogenesis. Cancer Res. 33: 1625-1627.
50. Rice JM (1973). The biological behaviour of transplacentally induced tumours in mice, Vol. 4. In: Transplacental Carcinogenesis, L Tomatis, U Mohr, and W Davis (eds). IARC Scientific Publication, Lyon, France, pp. 71-83.
51. Roe FJC, Rowson KEK, and Salaman MH (1961). Tumours of many sites induced by injection of chemical carcinogens into newborn mice. A sensitive test for carcinogenesis: The implications for certain immunologic theories. Br. J. Cancer 15: 515-518.
52. Ruebner BH, Bannasch P, Hinton D, Cullen J, and Ward JM (1995). Foci of altered hepatocytes, mouse. In: Monographs on Pathology of Laboratory Animals, TC Jones and U Mohr (eds). Digestive System, 2nd ed. (in press).
53. Ruebner BH, Gershwin ME, Meierhenry EF, Hsieh LS, and Dunn PL (1984) Irreversibility of liver tumors in C3H mice. J. Natl. Cancer Inst. 73: 493-498.
54. Sanchez IM and Bull RJ (1990). Early induction of reparative hyperplasia in the liver of B6C3F1 mice treated with dichloroacetate and trichloroacetate. Toxicology 64: 33-46.
55. Sandgren EP (1995). Transgenic mouse models of hepatic growth regulation and hepatocarcinogenesis. In: Liver Regeneration and Carcinogenesis: Molecular and Cellular Mechanisms, R Jirtle (ed). Academic Press, Inc. (in press).
56. 1 mice by unleaded gasoline. Environ. Health Perspect. 103: 696-700.
57. Schulte-Hermann R, Timmermann-Trosiener I, and Schuppler J (1983). Promotion of spontaneous preneoplastic cells in rat liver as a possible explanation of tumor production by nonmutagenic compounds. Cancer Res. 43: 839-844.
58. Siglin JC, Weghorst CM, and Klaunig JE (1991). Role of hepatocyte proliferation in α-hexachlorocyclohexane and phenobarbital tumor promotion in B6C3F1 mice. Prog. Clin. Biol. Res. 369: 407-416.
59. Tamano S, Merlino GT, and Ward JM (1994). Rapid development of hepatic tumors in transforming growth factor α transgenic mice associated with increased cell proliferation in precancerous hepatocellular lesions initiated by N-nitrosodiethylamine and promoted by phenobarbital. Carcinogenesis 15: 1791-1798.
60. 344 rats and (C57BL/6N × C3H/HeN)Fi(B6C3F1) mice. J. Natl. Cancer Inst. 66: 1175-1181.
61. Tatematsu M, Fukami H, Yamamoto M, Nakanishi H, Masui T, Kusakabe N, and Sakakura T (1994). Clonal analysis of glandular stomach carcinogenesis in C3H/HeN↔BALB/c chimeric mice treated with N-methyl-N-nitrosourea. Cancer Lett. 83: 37-42.
62. Thomas GA, Williams D, and Williams ED (1991). Reversibility of the malignant phenotype in monoclonal tumours in the mouse. Br. J. Cancer 63: 213-216.
63. Tomatis L, Aitio A, Wilbourn J, and Shuker L (1989). Human carcinogens so far identified. Jpn. J. Cancer Res. 80: 795-807.
64. Tomatis L, Partensky C, and Montesano R (1973). The predictive value of mouse liver tumour induction in carcinogenicity testing: A literature survey. Int. J. Cancer 12: 1-20.
65. Tsutsui T, Komine A, Huff J, and Barrett JC (1995). Effects of testosterone, testosterone propionate, 17β-trenbolone and progesterone on cell transformation and mutagenesis in Syrian hamster embryo cells. Carcinogenesis 16:1329-1333.
66. Tsuji S, Ogawa K, Takasaka H, Sonoda T, and Mori M (1988). Clonal origin of gamma-glutamyl transpeptidase-positive hepatic lesions induced by initiation-promotion of ornithine carbamoyl-transferase mosaic mice. Jpn. J. Cancer Res. (Gann) 79:148-151.
67. Vesselinovitch SD (1980). Infant mouse as a sensitive bioassay system for carcinogenicity of N-nitroso compounds. In: N-Nitroso Compounds: Analysis, Formation and Occurrence, EA Walker, M Castegnareo, L Gricuite, and M Borzsonyi (eds). IARC Scientific Publication No. 31, Lyon, pp. 645-655.
68. Vesselinovitch SD (1990). Perinatal mouse liver carcinogenesis as a sensitive carcinogenesis model and the role of the sex hormonal environment in tumor development. Prog. Clin. Biol. Res. 331: 53-68.
69. Vesselinovitch SD and Mihailovich N (1984). Kinetics of induction and growth of basophilic foci and development of hepatocellular carcinoma by diethyl-nitrosamine in the infant mouse. In: Mouse Liver Neoplasia: Current Perspectives. CIIT Series, JA Popp (ed). Hemisphere, New York, pp. 61-83.
70. Vesselinovitch SD, Rao KVN, and Mihailovoch N (1979). Neoplastic response of mouse tissue during perinatal age periods and its significance in chemical carcinogenesis. J. Natl. Cancer Inst. 51: 239-250.
71. Ward JM (1980). Morphology of hepatocellular neoplasms in B6C3F1 mice. Cancer Lett. 9: 319-325.
72. Ward JM (1984). Morphology of potential preneoplastic hepatocyte lesions and liver tumors and a comparison with other species. In: Mouse Liver Neoplasia, JA Popp (ed). Hemisphere, Washington, D.C., pp. 1-26.
73. Ward JM (1983). Increased susceptibility of livers of aged F344/ NCr rats to the effects of phenobarbital on the incidence, morphology, and histochemistry of hepatocellular foci and neoplasms. J. Natl. Cancer Inst. 71: 815-823.
74. Ward JM, Rice JM, Creasia D, Lynch P, and Riggs C (1983). Dissimilar patterns of promotion by di(2-ethylhexyl)phthalate and phenobarbital of hepatocellular neoplasia initiated by diethyl-nitrosamine in B6C3F1 mice. Carcinogenesis 4: 1021-1029.
75. Ward JM, Anver MR, Haines DC, and Benveniste RE (1994). Chronic active hepatitis in mice caused by Helicobacter hepaticus. Am. J. Pathol. 145: 959-968.
76. Ward JM, Diwan BA, Lubet RA, Henneman JR, and Devor DE (1990). Liver tumor promoters and other mouse liver carcinogens. Prog. Clin. Biol. Res. 331: 85-108.
77. Ward JM, Diwan BA, Ohshima M, Hu H, Schuller HM, and Rice JM (1986). Tumor-initiating and promoting activities of di(2-ethylhexyl) phthalate in vivo and in vitro. Environ. Health Perspect. 65: 279-291.
78. Ward JM, Fox JG, Anver MR, Haines DC, George CV, Collins MJ Jr, Gorelick PL, Nagashima K, Gonda MA, Gilden RV, Tully JG, Russell RJ, Benveniste RE, Paster BJ, Dewhirst FE, Donovan JC, Anderson LM, and Rice JM (1994a). Chronic active hepatitis and associated liver tumors in mice caused by a persistent bacterial infection with a novel Helicobacter species. J. Natl. Cancer Inst. 86: 1222-1227.
79. Ward JM, Griesemer RA, and Weisburger EK (1979). The mouse liver tumor as an endpoint in carcinogenesis tests. Toxicol. Appl. Pharmacol. 51: 389-397.
80. Ward JM, Lynch P, and Riggs C (1988). Rapid development of hepatocellular neoplasms in aging male C3H/HeNCr mice given phenobarbital. Cancer Lett. 39: 9-18.
81. Ward JM, Ohshima M, Lynch P, and Riggs C (1984). Di(2-ethylhexyl)phthalate but not phenobarbital promotes N-nitrosodiethylamine-initiated hepatocellular proliferation lesions after short-term exposure in male B6C3F1 mice. Cancer Lett. 24: 49-55.
82. Ward JM, Perantoni AO, and Santos E (1989). Comparative immunohistochemical reactivity of monoclonal and polyclonal antibodies to H-ras p21 in normal and neoplastic tissues of rodents and humans. Oncogene 4: 203-213.
83. Ward JM, Uno H, Kurata Y, Weghorst CM, and Jang J-J (1993). Cell proliferation not associated with carcinogenesis in rodents and humans. Environ. Health Perspect. 101 (suppl.) 5: 125-136.
84. Ward JM and Vlahakis G (1978). Evaluation of hepatocellular neoplasms in mice. J. Natl. Cancer Inst. 61: 807-811.
85. Williams GM and Weisburger JH (1991). Chemical carcinogenesis. In: Casarett and Doull's Toxicology, MO Amdur, J Doull, and CD Klassen (eds). Pergamon Press, New York, pp. 127-200.
86. Wiseman RW, Stowers SJ, Miller EC, Anderson MW, and Miller JA (1986). Activating mutations of the c-Ha-ras protooncogene in chemically induced hepatomas of the male B6C3F1 mouse. Proc. Natl. Acad. Sci. USA 83: 5825-5829.
87. Yamamoto R, Iishi H, Tatsuta M, Tsuji M, and Terada N (1991). Roles of ovaries and testes in hepatocellular tumorigenesis induced in mice by 3′-methyl-4-dimethylaminoazobenzene. Int. J. Cancer 49: 83-88.